Cerebral palsy in Canada, 2011-2031: results of a microsimulation modelling study of epidemiological and cost impacts. / La paralysie cérébrale au Canada, 2011-2031 : résultats d'une étude de modélisation par microsimulation des répercussions épidémiologiques et économiques.

INTRODUCTION: The objective of our study was to present model-based estimates and projections on current and future health and economic impacts of cerebral palsy in Canada over a 20-year time horizon (2011-2031). METHODS: We used Statistics Canada's Population Health Model (POHEM)-Neurological to simulate individuals' disease states, risk factors and health determinants and to describe and project health outcomes, including disease incidence, prevalence, life expectancy, health-adjusted life expectancy, health-related quality of life and health care costs over the life cycle of Canadians. Cerebral palsy cases were identified from British Columbia's health administrative data sources. A population-based cohort was then used to generate the incidence and mortality rates, enabling the projection of future incidence and mortality rates. A utility-based measure (Health Utilities Index Mark 3) was also included in the model to reflect various states of functional health to allow projections of health-related quality of life. Finally, we estimated caregiving parameters and health care costs from Canadian national surveys and health administrative data and included them as model parameters to assess the health and economic impact of cerebral palsy. RESULTS: Although the overall crude incidence rate of cerebral palsy is projected to remain stable, newly diagnosed cases of cerebral palsy will rise from approximately 1800 in 2011 to nearly 2200 in 2031. In addition, the number of people with the condition is expected to increase from more than 75 000 in 2011 to more than 94 000 in 2031. Direct health care costs in constant 2010 Canadian dollars were about $11 700 for children with cerebral palsy aged 1-4 years versus about $600 for those without the condition. In addition, people with cerebral palsy tend to have longer periods in poorer health-related quality of life. CONCLUSION: Individuals with cerebral palsy will continue to face challenges related to an ongoing need for specialized medical care and a rising need for supportive services. Our study offers important insights into future costs and impacts associated with cerebral palsy and provides valuable information that could be used to develop targeted health programs and strategies for Canadians living with this condition.

A life satisfaction approach to valuing the impact of health behaviours on subjective well-being.

BACKGROUND: Increasingly, decision-makers are interested in understanding the returns on investments in programs and policies that promote health and prevent chronic diseases. While the costs of these programs are more easily quantified, many of the outcomes they aspire to achieve are intangible and lack obvious market values. The subjective well-being (SWB) method was developed to value a wide range of non-market goods, including health outcomes directly in monetary terms. This paper presents an application of the SWB approach to estimate the monetary value of health-promoting behaviours as the intermediate outcomes of health promotion and chronic disease prevention programs and policies. METHODS: Life satisfaction (LS) was used as a proxy of individuals' SWB. Based on the combined Canadian Community Health Survey 2009-10 data, we modeled LS as a function of income and healthy behaviours, controlling for the socio-demographic factors associated with LS at the individual level using ordinary least squares regression. Equivalent effects of income and healthy behaviours on LS derived from the models allowed us to estimate the trade-off between income and healthy behaviours. RESULTS: We found that income and healthy behaviours were positively associated with LS. The values of increased physical activity, an additional daily serving of fruits/vegetables, and not smoking are respectively $631, $115 and $563 per week. These represent the amounts of additional weekly income required to maintain an individual at their level of LS in the absence of each of these behaviours. CONCLUSIONS: The SWB method holds promise as a method to monetize the value of a range of non-market goods, including healthy behaviours for which market values do not exist. The SWB method can be applied efficiently and cost-effectively using readily available survey data.

Development of a population-based microsimulation model of body mass index.

BACKGROUND: The increasing prevalence of overweight and obesity has necessitated the development of body mass index (BMI) projection models such as the POpulation HEalth Model (POHEM). This study describes the POHEM-BMI model, a microsimulation tool that can be used to support evidence-based health policy making for obesity reduction. DATA AND METHODS: The National Population Health Survey, the Canadian Community Health Survey (CCHS), and the Canadian Health Measures Survey (CHMS) were used to develop and validate a predictive model of BMI for adults and childhood BMI history. Models were incorporated into POHEM and used to transition BMI over time in a fully dynamic simulated Canadian population. RESULTS: POHEM-BMI projections of self-reported and measured adult BMI and childhood BMI history agree well with CCHS and CHMS validation estimates. Among men and women, average BMI is projected to increase by more than one BMI unit between 2001 and 2030. Projections of self-reported BMI show that 59% of the adult population will be overweight or obese by 2030; projections of measured BMI show that the percentage will be 66%. INTERPRETATION: Using empirically developed BMI prediction models for adults and childhood BMI history integrated into the POHEM framework, validated projections of BMI for the Canadian population can be produced. Projections of BMI trends could have important applications in tracking the prevalence of related diseases, and in planning and comparing intervention strategies.

Multiple sclerosis in Canada 2011 to 2031: results of a microsimulation modelling study of epidemiological and economic impacts. / La sclérose en plaques au Canada, 2011-2031 : résultats d'une étude de modélisation par microsimulation des répercussions épidémiologiques et économiques.

INTRODUCTION: The objective of our study was to present model-based estimates and projections on current and future health and economic impacts of multiple sclerosis (MS) in Canada over a 20-year time horizon (2011-2031). METHODS: Using Statistics Canada's Population Health Microsimulation Model (POHEM) framework, specifically the population-based longitudinal, microsimulation model named POHEM-Neurological, we identified people with MS from health administrative data sources and derived incidence and mortality rate parameters from a British Columbia population-based cohort for future MS incidence and mortality projections. We also included a utility-based measure (Health Utilities Index Mark 3) reflecting states of functional health to allow projections of health-related quality of life. Finally, we estimated caregiving parameters and health care costs from Canadian national surveys and health administrative data and included them as model parameters to assess the health and economic impact of the neurological conditions. RESULTS: The number of incident MS cases is expected to rise slightly from 4051 cases in 2011 to 4794 cases per 100 000 population in 2031, and the number of Canadians affected by MS will increase from 98 385 in 2011 to 133 635 in 2031. The total per capita health care cost (excluding out-of-pocket expenses) for adults aged 20 and older in 2011 was about $16 800 for individuals with MS, and approximately $2500 for individuals without a neurological condition. Thus, after accounting for additional expenditures due to MS (excluding out-of-pocket expenses), total annual health sector costs for MS are expected to reach $2.0 billion by 2031. As well, the average out-of-pocket expenditure for people with MS was around $1300 annually throughout the projection period. CONCLUSION: MS is associated with a significant economic burden on society, since it usually affects young adults during prime career- and family-building years. Canada has a particularly high prevalence of MS, so research such as the present study is essential to provide a better understanding of the current and future negative impacts of MS on the Canadian population, so that health care system policymakers can best plan how to meet the needs of patients who are affected by MS. These findings also suggest that identifying strategies to prevent MS and more effectively treat the disease are needed to mitigate these future impacts.

INTRODUCTION: L'objectif de notre étude est de présenter des estimations et des projections des répercussions épidémiologiques et économiques de la sclérose en plaques (SP) au Canada sur 20 ans (2011-2031). MÉTHODOLOGIE: Nous avons utilisé un modèle de microsimulation de la santé de la population (POHEM) de Statistique Canada, plus précisément le modèle longitudinal de microsimulation démographique appelé POHEM - Maladies neurologiques. Nous avons sélectionné les personnes atteintes de SP à partir de sources de données administratives sur la santé et dérivé les paramètres liés à l'incidence de la maladie et au taux de décès d'une étude de cohorte de la Colombie-Britannique afin de prévoir quels seront l'incidence de la SP et son taux de décès. Nous avons également inclus une mesure reposant sur l'utilité (Health Utilities Index Mark 3) qui rend compte des états de santé fonctionnelle afin de réaliser des projections sur la qualité de vie liée à la santé. Enfin, nous avons estimé les paramètres de prestation de soins et de coûts des soins de santé à partir de sondages nationaux du Canada et de données administratives sur la santé et nous les avons inclus comme paramètres dans le modèle visant à évaluer les répercussions économiques et sur la santé des maladies neurologiques. RÉSULTATS: On anticipe une légère augmentation du nombre de cas incidents de SP, passant de 4 051 cas pour 100 000 personnes en 2011 à 4 974 en 2031. Le nombre de Canadiens touchés par la SP passera ainsi de 98 385 en 2001 à 133 635 en 2031. Le coût total des soins de santé par personne (à l'exception des dépenses directes) pour les adultes de 20 ans et plus atteints de SP en 2011 était d'environ 16 800 $, contre un peu moins de 2500 $ pour ceux ne souffrant d'aucune affection neurologique. Si on comptabilise les dépenses supplémentaires liées à la SP (à l'exception des dépenses directes), les coûts totaux annuels de la SP pour le secteur de la santé devraient donc atteindre deux milliards de dollars d'ici 2031. Par ailleurs, les dépenses directes moyennes des personnes atteintes de SP seront d'environ 1300 $ par année tout au long de la période de projection. CONCLUSION: La SP est associée à un important fardeau économique pour la société car elle touche surtout de jeunes adultes à un moment fondateur pour leur vie professionnelle et leur vie familiale. Sa prévalence étant particulièrement élevée au Canada, des recherches comme la nôtre sont essentielles afin de mieux comprendre les répercussions actuelles et futures de la SP sur la population canadienne, afin que les décideurs du réseau de la santé puissent mieux planifier les besoins en soins de santé pour les malades qui en sont atteints. Selon ces résultats, des stratégies pour prévenir la SP et la traiter plus efficacement sont essentielles pour en atténuer les futures répercussions.

Impact of the international term breech trial on clinical practice and concerns: a survey of centre collaborators.

OBJECTIVE: The purpose of this study was to determine what impact the International Term Breech Trial had had in different settings and to elicit any concerns among collaborators regarding the implementation of a policy of planned Caesarean section for term breech babies. METHODS: We mailed a questionnaire to all Term Breech Trial collaborators. The questionnaire asked 3 open-ended questions about the impact of the trial, about concerns with implementing planned Caesarean section for term breech babies, and about whether information as to the relative costs of planned Caesarean section versus planned vaginal birth would be helpful. Frequencies of responses were calculated for centres in countries classified as having a low or a high national perinatal mortality rate (< or = 20/1000 vs. > 20/1000, respectively) according to the figures published by the World Health Organization in 1996. RESULTS: We received responses from 80 centres in 23 countries. Most centres (92.5%) stated that clinical practice had changed to planned Caesarean section for most or all term breech babies. The majority of centres (66.3%) had no difficulties or concerns with implementing a policy of planned Caesarean section for term breech babies. Most centres (85.0%) indicated that an analysis of relative costs would not affect clinical practice in their setting. CONCLUSION: Clinical practice has changed to planned Caesarean section in most collaborating centres, given the results of the Term Breech Trial.